AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
- Conditions
- LymphomaNHLNon-Hodgkin Lymphoma
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2009-09-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00471367
- Locations
- 🇺🇸
Research Site, Greenville, South Carolina, United States
Phase 3/Safety & Efficacy of Esomeprazole in Infants
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Drug: Open Label Run In EsomeprazoleDrug: Double Blind EsomeprazoleDrug: Double Blind Placebo
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00468559
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])Drug: pramlintide acetate (Symlin)Drug: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT00467649
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Local Phase 4 Pan-European SMART Study
- Conditions
- Asthma
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2010-03-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8424
- Registration Number
- NCT00463866
- Locations
- 🇬🇧
Research Site, Yaxley, United Kingdom
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00463814
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
- Conditions
- HypercholesterolemiaDyslipidemia
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 760
- Registration Number
- NCT00463606
- Locations
- 🇺🇸
Site Reference ID/Investigator# 4387, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 5585, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 4483, Gilbert, Arizona, United States
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
- Conditions
- Lymphoma
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00460460
- Locations
- 🇺🇸
Research site, Buffalo, New York, United States
🇨🇦Research Site, Toronto, Ontario, Canada
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
- Conditions
- Psychotic DisordersSchizophreniaSchizoaffective Disorders
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00457899
- Locations
- 🇬🇧
Research Site, Warrington, United Kingdom
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00454805
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
AZD8330 First Time in Man in Patients With Advanced Malignancies
- Conditions
- Cancer
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT00454090
- Locations
- 🇳🇴
Research Site, Oslo, Norway